Next Article in Journal
Using Real-Life Data to Strengthen the Education of Pharmacy Technician Students: From Student to Research Assistant
Previous Article in Journal
Relationship between 2-Hour Tacrolimus Concentrations and Clinical Outcomes in Long Term Kidney Transplantation
Open AccessArticle

Assessing Pharmacists’ Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis

1
Department of Pharmacy, Hospital Universitari Son Espases, 07120 Palma, Balearic Islands, Spain
2
Medical Department, Roche Farma S.A., 28042 Madrid, Spain
3
Department of Pharmacy, Hospital Universitario Fundación Alcorcón, 28922 Alcorcón, Madrid, Spain
4
Department of Pharmacy, Hospital Universitario de Fuenlabrada, 28942 Fuenlabrada, Madrid, Spain
5
Department of Pharmacy, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain
6
Department of Pharmacy, Hospital Universitario Virgen de la Victoria, 29010 Málaga, Spain
7
Department of Pharmacy, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain
8
Market Access Department, Roche Farma S.A., 28042 Madrid, Spain
9
Health Economics and Outcomes Research, IQVIA Information S.A., 08025 Barcelona, Spain
*
Author to whom correspondence should be addressed.
Pharmacy 2020, 8(2), 61; https://doi.org/10.3390/pharmacy8020061
Received: 9 March 2020 / Revised: 30 March 2020 / Accepted: 5 April 2020 / Published: 7 April 2020
(This article belongs to the Section Clinical Pharmacy)
Introduction: Hospital pharmacists are increasingly playing a critical role in the care of patients with multiple sclerosis (MS). However, little is known about their preferences and perspectives towards different attributes of disease-modifying therapies (DMTs). The objective of this research was to assess pharmacists´ preferences for DMT efficacy attributes. Methods: A multicenter, non-interventional, cross-sectional, web-based study was conducted. Preventing relapses, delaying disease progression, controlling radiological activity, and preserving health-related quality of life (HRQoL) and cognition were the attributes selected based on a literature review and a focus group with six hospital pharmacists. Conjoint analysis was used to determine preferences in eight hypothetical treatment scenarios, combining different levels of each attribute and ranking them from most to least preferred. Results: Sixty-five hospital pharmacists completed the study (mean age: 43.5 ± 7.8 years, 63.1% female, mean years of professional experience: 16.1 ± 7.4 years). Participants placed the greatest preference on delaying disease progression (35.7%) and preserving HRQoL (21.6%) and cognition (21.6%). Importance was consistent in all groups of pharmacists stratified according to demographic characteristics, experience, research background, and volume of patients seen per year. Conclusions: Understanding which treatment characteristics are meaningful to hospital pharmacists may help to enhance their synergistic role in the multidisciplinary management of patients with MS. View Full-Text
Keywords: multiple sclerosis; pharmacist; preferences; disease-modifying therapy; disease progression multiple sclerosis; pharmacist; preferences; disease-modifying therapy; disease progression
Show Figures

Figure 1

MDPI and ACS Style

Martínez-López, I.; Maurino, J.; Sanmartín-Fenollera, P.; Ontañon-Nasarre, A.; Santiago-Pérez, A.; Moya-Carmona, I.; García-Collado, C.G.; Fernández-Del Olmo, R.; García-Arcelay, E.; Sarmiento, M.; Carreño, Á.; Pérez-Encinas, M. Assessing Pharmacists’ Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis. Pharmacy 2020, 8, 61.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop